

# Table of Contents

## Special Issue on Cancer burden in China: Epidemiology, etiology, and prevention

### Preface

- 879 Preface to Special Issue: Cancer burden in China: Epidemiology, etiology, and prevention  
*Jiafu Ji*

### Review Article

- 882 Epidemiology, early detection, and management of breast cancer in China: A comprehensive review  
*Hangcheng Xu, Binghe Xu*
- 900 Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century  
*Lijuan Hu, Yi Xia, Xiaojun Huang*
- 912 Cancer statistics in China: Epidemiology, risk factors, and prevention  
*Wei Cao, Kang Qin, Bingyang Liu, Wanqing Chen*
- 929 Evolving diagnostic and surveillance strategies in esophageal cancer screening: Evidence from population-based studies in China  
*Zhongbu He, Yang Ke*
- 937 Gastric cancer in China: Epidemiology, risk factors, and screening  
*Yuxin Wang, Zongchao Liu, Wenqing Li, Yang Zhang, Kaifeng Pan*

### Guidelines

- 949 National Health Commission guidelines for diagnosis and treatment of colorectal cancer in China (2025 edition, English version)  
*Department of Medical Administration, National Health Commission of the People's Republic of China; Chinese Medical Association Oncology Branch*

### Original Article

- 962 Factors associated with neoadjuvant therapy insensitivity and its prognostic impact in HER2-positive breast cancer  
*Yubang Han, Bo Lan, Zexi Peng, Yueran Jia, Danyang Ji, Xinzhu Tian, Yuanting Yang, Die Sang, Xuemin Xue, Jiayu Wang, Fei Ma, Yang Luo, Pin Zhang, Binghe Xu, Ying Fan*

- 973 Diagnostic sensitivity of mammography and magnetic resonance imaging for ductal carcinoma *in situ* in high-risk breast cancer screening: A systematic-review and meta-analysis**  
*Mengmeng Li, Yixuan Lin, Keris Poelbekken, Marcel J.W. Greuter, Geertruida H. de Bock, Monique D. Dorrius*
- 984 A multicenter study of a predictive model for pathological complete response after neoadjuvant therapy in breast cancer using multimodal digital biomarkers**  
*Zixuan Yang, Jie He, Taolang Li, Changdong Liu, Yongseng Wang, Yu Ren, Wenhe Zhao, Choo Chiap Chiau, Qiang Li, Liang Xu, Jian Yue, Ting Liang, Lidan Jin, Xiaoyu Fang, Bobui Shi, Zhiqiang Shi, Peng Yuan, Michael Gnant*
- 1000 Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: Targeting *SLC25A1* to overcome immune resistance**  
*Pengpeng Zhang, Xiaoqing Liang, Bicheng Ye, Xiaofei Wang, Yijie Wang, Zetian Gong, Yuming Huang, Jinyang Liu, Chenjun Huang, Peng Luo*
- 1020 Development and validation of a clinical risk-prediction model for immune checkpoint inhibitor-related pneumonitis in patients with gastrointestinal cancer based on four machine learning algorithms**  
*Yixuan Wang, Liyan Zhang, Zhenzhen Su, Xuemin Lian, Zhibao Lu*
- 1034 Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer**  
*Facai Zhang, Yunkai Yang, Rong Zhang, Huan Hu, Chuanzan Zhou, Jie Wang, Ruicheng Wu, Enbui Li, William C. Cho, Dabong Zhang, Qi Zhang, Dechao Feng*

## Commentary

- 1058 Hematology specialist nurse-led continuity-of-care for high-risk hematopoietic cell transplantation recipients**  
*Ting Wang, Li Wu, Aiyun Jin, Xiaming Zhu, Wenjun Xie, Yun Fang, Yanyan Chai, Songhua Luan, Xin Du, Michelle Kenyon, Xia Yan*

## Corrigendum

- 1062 Corrigendum to Discovery and validation of indole nitroolefins as novel covalent GPX4 inhibitors for inducing ferroptosis in urological cancers**